Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

PartnershipREGN20423Long-acting IL-4xIL-13 bispecificPositive

AI Analysis

Summary

Regeneron and Sanofi expanded their global alliance to include REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody, along with additional long-acting immunology antibodies in development. The expansion adds multiple next-generation therapeutic candidates to their existing collaboration.

Outcome Details

Expansion of global alliance with addition of multiple next-generation, long-acting immunology antibodies

Importance:7/10

Sentiment:

0.60

partnershipimmunologymonoclonal_antibodyalliance_expansionlong-acting_therapeutics

Related Companies

$REGN $SNY

Read the original article

Published by GlobeNewswire Pharma on October 1, 2026 5:00 AM

Read Original